4.7 Article

NK cells are negatively regulated by sCD83 in experimental autoimmune uveitis

期刊

SCIENTIFIC REPORTS
卷 7, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-017-13412-1

关键词

-

资金

  1. Natural Science Foundation of China [81370730, 81571512]
  2. Shandong Province Natural Science Foundation [ZR2015JL027, ZR2015HL052]
  3. Projects of medical and health technology development program in Shandong province [2015WS0194]
  4. Shandong Academy of Medical Sciences [2015-25, 2015-27]
  5. Department of Health and Family-plan Bureau, Shandong Province [2015WS0189, 2015WS0195, 2015WS0188]
  6. Shandong Academy of Medical Sciences

向作者/读者索取更多资源

Natural killer (NK) cells represent a subset of lymphocytes that contribute to innate immunity and have been reported to play a role in autoimmune uveitis. However, the mechanisms regulating NK cellular function in this condition remain unclear. Herein, we investigated the status of NK cells in experimental autoimmune uveitis (EAU). We found that the number of CD83(+) CD3-NK1.1(+) cells was increased in the inflamed eyes and spleens of the EAU mouse model. At the recovery stage of EAU, serum concentrations of soluble CD83 (sCD83) were increased. sCD83 treatment relieved retinal tissue damage and decreased the number of infiltrating NK cells in inflamed eyes. Further analysis of the effects of sCD83 treatment in EAU revealed that it reduced: 1) the expressions of CD11b and CD83 in NK cells, 2) the percent of CD11b(high)CD27(low)CD3-NK1.1(+) cells and 3) the secretion of granzyme B, perforin and IFN-gamma in NK cells as demonstrated both in vivo and in vitro. When sCD83 treated-NK cells were transferred into EAU mice, retinal tissue damage was relieved. These results demonstrate sCD83 down-regulate NK cellular function and thus provide important, new information regarding the means for the beneficial effects of this agent in the treatment of autoimmune uveitis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据